An ongoing phase 3 trial, the SELECT study, will evaluate the cardiovascular benefit of semaglutide beyond blood glucose control, as the study population is composed of individuals who are overweight or obese without diabetes [81]
What standards does Strive follow
A critical finding from independent peptide testing: GLP-1 receptor agonists and related peptides show the highest discrepancy rates of any peptide category, with only 27% of supplier-provided COAs exactly matching independent laboratory results
Ozempic is approved for managing diabetes, while Wegovy (semaglutide GLP-1) is tailored for weight loss, with a higher dose typically prescribed for individuals struggling with obesity
Some people release too little GLP-1, resulting in overeating and snacking between meals
Tirzepatide, a dual GIP/GLP-1 receptor agonist, has a slightly different receptor activity profile and may be tolerated differently, though gastrointestinal side effects remain common